KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential ...
About KOMZIFTI™ KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation ...
Kura Oncology's partnership with Kyowa Kirin centered on ziftomenib offers long-term benefits, however, commercialization and significant royalties will take time to materialize. Ziftomenib, Kura's ...
Fintel reports that on October 20, 2025, JMP Securities reiterated coverage of Kura Oncology (NasdaqGS:KURA) with a Market Outperform recommendation. Analyst Price Forecast Suggests 175.68% Upside As ...
Fintel reports that on November 24, 2025, Barclays maintained coverage of Kura Oncology (NasdaqGS:KURA) with a Overweight recommendation. Analyst Price Forecast Suggests 182.25% Upside As of November ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback